AR120719A1 - GLYCOSYLATED ANTIBODIES AGAINST THE INSULIN-LIKE GROWTH FACTOR I RECEPTOR AND THEIR USES - Google Patents

GLYCOSYLATED ANTIBODIES AGAINST THE INSULIN-LIKE GROWTH FACTOR I RECEPTOR AND THEIR USES

Info

Publication number
AR120719A1
AR120719A1 ARP200103440A ARP200103440A AR120719A1 AR 120719 A1 AR120719 A1 AR 120719A1 AR P200103440 A ARP200103440 A AR P200103440A AR P200103440 A ARP200103440 A AR P200103440A AR 120719 A1 AR120719 A1 AR 120719A1
Authority
AR
Argentina
Prior art keywords
insulin
receptor
growth factor
antibodies against
glycosylated antibodies
Prior art date
Application number
ARP200103440A
Other languages
Spanish (es)
Inventor
Anne Odonnell
Patrick Michael Jennings
Edel Mullen
Original Assignee
Horizon Therapeutics Ireland Designated Activity Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Therapeutics Ireland Designated Activity Company filed Critical Horizon Therapeutics Ireland Designated Activity Company
Publication of AR120719A1 publication Critical patent/AR120719A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Una composición que comprende una pluralidad de anticuerpos monoclonales recombinantes (mAb), de secuencia idéntica, que se unen al receptor del factor de crecimiento I similar a la insulina (IGF-IR), en la que cada mAb comprende dominios constantes de cadena pesada de IgG1 o IgG3 humana glicosilados con una cadena de azúcar en Asn297, donde dichos mAb se caracterizan porque el 96 - 98% de las cadenas de azúcar tienen al menos un grupo fucosilo y cada cadena de azúcar tiene de aproximadamente 1 - 3% de derivados del ácido siálico, 1% o menos de a-1,3-galactosa y aproximadamente 35 - 40% de galactosa y usos de esta.A composition comprising a plurality of recombinant monoclonal antibodies (mAbs) of identical sequence that bind to the insulin-like growth factor I receptor (IGF-IR), wherein each mAb comprises heavy chain constant domains of Glycosylated human IgG1 or IgG3 with a sugar chain at Asn297, wherein said mAbs are characterized in that 96-98% of the sugar chains have at least one fucosyl group and each sugar chain has approximately 1-3% fucosyl derivatives. sialic acid, 1% or less of α-1,3-galactose and about 35-40% galactose and uses thereof.

ARP200103440A 2019-12-10 2020-12-10 GLYCOSYLATED ANTIBODIES AGAINST THE INSULIN-LIKE GROWTH FACTOR I RECEPTOR AND THEIR USES AR120719A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962946230P 2019-12-10 2019-12-10

Publications (1)

Publication Number Publication Date
AR120719A1 true AR120719A1 (en) 2022-03-09

Family

ID=76330772

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200103440A AR120719A1 (en) 2019-12-10 2020-12-10 GLYCOSYLATED ANTIBODIES AGAINST THE INSULIN-LIKE GROWTH FACTOR I RECEPTOR AND THEIR USES

Country Status (2)

Country Link
AR (1) AR120719A1 (en)
WO (1) WO2021119234A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021243014A1 (en) * 2020-05-28 2021-12-02 Horizon Therapeutics Ireland Dac Methods for the treatment of idiopathic orbital inflammation and related conditions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080014203A1 (en) * 2006-04-11 2008-01-17 Silke Hansen Antibodies against insulin-like growth factor I receptor and uses thereof

Also Published As

Publication number Publication date
WO2021119234A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
BR112017019978A2 (en) antibody or antigen-binding fragment, conjugate, antigen receptor, strand, strand conjugate, fusion protein, t-cell, polynucleotide, vector, ex vivo cell, method of producing a chain, method of producing an antibody, pharmaceutical composition , method for treating cancer, glycopeptide, method for generating an antibody
AR110017A1 (en) PD-1 ANTIBODIES AND USES OF THESE
CL2023001076A1 (en) Anti-ccr8 monoclonal antibodies and their uses.
CL2022002555A1 (en) Anti-ccr8 antibodies for cancer treatment
PE20120899A1 (en) COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING COMPLEMENT PROTEIN C3B
AR120563A1 (en) CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES
PE20191463A1 (en) BISPECIFIC ANTIBODIES OF SPECIFIC JOINT PD1 AND LAG3
AR095115A1 (en) ANTIBODIES UNDERSTANDING CHEMICAL CONSTANT DOMAINS
MX2019013132A (en) Antibodies comprising modified heavy constant regions.
AR111362A1 (en) ANTI-ILT4 ANTIBODIES AND ANTIGEN UNION FRAGMENTS
CO2019012143A2 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with antibodies against programmed death receptor 1 (pd-1) and methods for their use
BRPI0821168B8 (en) isolated antibody that binds to human IL-21, or a fragment thereof, uses of said antibody or fragment, and, hybridoma
MX2017006323A (en) Antibodies comprising modified heavy constant regions.
CO6251371A2 (en) AN ANTI-CD37 ANTIBODY DERIVED FROM A MURINO MONOCLONAL ANTIBODY
AR106184A1 (en) PD-1 BINDING PROTEINS AND THEIR METHODS OF USE
AR071698A1 (en) ANTIBODIES AGAINST THE RECEIVER OF ADVANCED GLICOSILATION (RAGE) FINAL PRODUCTS AND USES OF THE SAME
CN110536900A (en) Adjust people's IGM constant region of the modification of complement dependent cellular solubility effect subfunction
CL2013003634A1 (en) Complex comprising a fusion protein comprising, a viral peptide, linker peptide, beta 2 microglobulin, linker peptide, extracellular domains alpha 1, 2 and 3 of mhc class i and a third linker peptide; Method of production; pharmaceutical formulation that includes it; and its use
AR062895A1 (en) COMPOSITIONS AND METHODS RELATED TO GLUCAGON RECEIVING ANTIBODIES
EA201792221A1 (en) ANTIBODIES AGAINST SORTILINE AND METHODS OF THEIR APPLICATION
PE20091196A1 (en) ANTIBODIES AGAINST COMPLETELY HUMAN VEGF, COMPOSITIONS AND METHODS
ECSP066681A (en) SOLID FORMS OF ANTI-EGFR ANTIBODIES
AR069130A1 (en) LINK MOLECULES OF THE MAIN COMPLEMENT OPSONIN (C3B) AND METHODS TO MODULATE THE COMPLEMENT COMPONENT
PE20180249A1 (en) NEUTRALIZING ANTIBODIES ANTI-CCL20
PE20081186A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALLERGIC DISEASES

Legal Events

Date Code Title Description
FB Suspension of granting procedure